The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine

The dose limiting factors of cisplatinum are nephrotoxicity and emesis. Nephrotoxicity has been reduced by hydration but nausea and vomiting caused by cisplatinum have led to refusal of potentially curative therapy by a number of patients. The prevention of nausea and vomiting by a combination of an...

Full description

Saved in:
Bibliographic Details
Published inNihon Sanka Fujinka Gakkai zasshi Vol. 39; no. 11; p. 1968
Main Authors Dozono, H, Yasuda, M, Yokoyama, S, Takahashi, S, Ochiai, K, Tsuruoka, M, Morimoto, O, Sasaki, H, Arihiro, T, Terashima, Y
Format Journal Article
LanguageJapanese
Published Japan 01.11.1987
Subjects
Adult
Antiemetics - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - adverse effects
Cyclophosphamide - administration & dosage
Dexamethasone - administration & dosage
Diphenhydramine - administration & dosage
Doxorubicin - administration & dosage
Droperidol - administration & dosage
Female
Fluorouracil - administration & dosage
Humans
Metoclopramide - administration & dosage
Middle Aged
Nausea - chemically induced
Nausea - prevention & control
Vomiting - chemically induced
Vomiting - prevention & control
Online AccessGet more information

Cover

More Information
Summary:The dose limiting factors of cisplatinum are nephrotoxicity and emesis. Nephrotoxicity has been reduced by hydration but nausea and vomiting caused by cisplatinum have led to refusal of potentially curative therapy by a number of patients. The prevention of nausea and vomiting by a combination of antiemetic drugs administered to ovarian patients receiving chemotherapy inducing (cisplatinum 50mg/m2, adriamycin 300 mg/m2, cyclophosphamide 300 mg/m2 and 5FU 350 mg/m2) was studied. the combination antiemetic drugs were metoclopramide (1mg/kg), dexamethasone (10mg/m2), droperidol (1mg/m2) and diphenhydramine (20mg/body). These drugs without diphenhydramine were administered intravenously 30 minutes before and 2.5 hours, 5 hours and 7.5 hours after chemotherapy. Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy. No vomiting was noted in 82.6% (19/23) of cases, and no patient vomited more than four times. This combination regimen provided very good protection against cisplatinum induced emesis.
ISSN:0300-9165